171 related articles for article (PubMed ID: 28003142)
1. Design, synthesis and biological activity of novel molecules designed to target PARP and DNA.
Goodfellow E; Senhaji Mouhri Z; Williams C; Jean-Claude BJ
Bioorg Med Chem Lett; 2017 Feb; 27(3):688-694. PubMed ID: 28003142
[TBL] [Abstract][Full Text] [Related]
2. Hypersensitivity of BRCA2 deficient cells to rosemary extract explained by weak PARP inhibitory activity.
Su C; Gius JP; Van Steenberg J; Haskins AH; Heishima K; Omata C; Iwayama M; Murakami M; Mori T; Maruo K; Kato TA
Sci Rep; 2017 Dec; 7(1):16704. PubMed ID: 29196727
[TBL] [Abstract][Full Text] [Related]
3. A type I combi-targeting approach for the design of molecules with enhanced potency against BRCA1/2 mutant- and O6-methylguanine-DNA methyltransferase (mgmt)- expressing tumour cells.
Senhaji Mouhri Z; Goodfellow E; Jean-Claude B
BMC Cancer; 2017 Aug; 17(1):540. PubMed ID: 28800752
[TBL] [Abstract][Full Text] [Related]
4. The Effect of Green and Black Tea Polyphenols on
Alqahtani S; Welton K; Gius JP; Elmegerhi S; Kato TA
Int J Mol Sci; 2019 Mar; 20(6):. PubMed ID: 30875717
[TBL] [Abstract][Full Text] [Related]
5. Design and synthesis of 2-(4,5,6,7-tetrahydrothienopyridin-2-yl)-benzoimidazole carboxamides as novel orally efficacious Poly(ADP-ribose)polymerase (PARP) inhibitors.
Chen X; Huan X; Liu Q; Wang Y; He Q; Tan C; Chen Y; Ding J; Xu Y; Miao Z; Yang C
Eur J Med Chem; 2018 Feb; 145():389-403. PubMed ID: 29335205
[TBL] [Abstract][Full Text] [Related]
6. Targeting on poly(ADP-ribose) polymerase activity with DNA-damaging hybrid lactam-steroid alkylators in wild-type and BRCA1-mutated ovarian cancer cells.
Trafalis DT; Polonifi A; Dalezis P; Nikoleousakos N; Katsamakas S; Sarli V
Chem Biol Drug Des; 2017 Nov; 90(5):854-866. PubMed ID: 28432813
[TBL] [Abstract][Full Text] [Related]
7. Identification of novel PARP-1 inhibitors: Drug design, synthesis and biological evaluation.
Xie Z; Zhou Y; Zhao W; Jiao H; Chen Y; Yang Y; Li Z
Bioorg Med Chem Lett; 2015 Oct; 25(20):4557-61. PubMed ID: 26342868
[TBL] [Abstract][Full Text] [Related]
8. Sulfoquinovosyl acylpropanediol (SQAP): Inhibition of poly(ADP-ribose) metabolism and enhanced cytotoxicity in homologous recombination repair-deficient Chinese hamster-derived cells.
Maeda J; Shellenberger KD; Kurihara W; Haga T; Kato TA
Mutat Res Genet Toxicol Environ Mutagen; 2023; 892():503703. PubMed ID: 37973295
[TBL] [Abstract][Full Text] [Related]
9. Poly (ADP-Ribose) Polymerases (PARPs) and PARP Inhibitor-Targeted Therapeutics.
Li N; Wang Y; Deng W; Lin SH
Anticancer Agents Med Chem; 2019; 19(2):206-212. PubMed ID: 30417796
[TBL] [Abstract][Full Text] [Related]
10. Design and Synthesis of Poly(ADP-ribose) Polymerase Inhibitors: Impact of Adenosine Pocket-Binding Motif Appendage to the 3-Oxo-2,3-dihydrobenzofuran-7-carboxamide on Potency and Selectivity.
Velagapudi UK; Langelier MF; Delgado-Martin C; Diolaiti ME; Bakker S; Ashworth A; Patel BA; Shao X; Pascal JM; Talele TT
J Med Chem; 2019 Jun; 62(11):5330-5357. PubMed ID: 31042381
[TBL] [Abstract][Full Text] [Related]
11. In silico investigation of PARP-1 catalytic domains in holo and apo states for the design of high-affinity PARP-1 inhibitors.
Salmas RE; Unlu A; Yurtsever M; Noskov SY; Durdagi S
J Enzyme Inhib Med Chem; 2016; 31(1):112-20. PubMed ID: 26083304
[TBL] [Abstract][Full Text] [Related]
12. Inhibitors of PARP: Number crunching and structure gazing.
Rudolph J; Jung K; Luger K
Proc Natl Acad Sci U S A; 2022 Mar; 119(11):e2121979119. PubMed ID: 35259019
[TBL] [Abstract][Full Text] [Related]
13. Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase.
Bryant HE; Schultz N; Thomas HD; Parker KM; Flower D; Lopez E; Kyle S; Meuth M; Curtin NJ; Helleday T
Nature; 2005 Apr; 434(7035):913-7. PubMed ID: 15829966
[TBL] [Abstract][Full Text] [Related]
14. Iniparib nonselectively modifies cysteine-containing proteins in tumor cells and is not a bona fide PARP inhibitor.
Liu X; Shi Y; Maag DX; Palma JP; Patterson MJ; Ellis PA; Surber BW; Ready DB; Soni NB; Ladror US; Xu AJ; Iyer R; Harlan JE; Solomon LR; Donawho CK; Penning TD; Johnson EF; Shoemaker AR
Clin Cancer Res; 2012 Jan; 18(2):510-23. PubMed ID: 22128301
[TBL] [Abstract][Full Text] [Related]
15. Discovery of quinazoline-2,4(1H,3H)-dione derivatives as novel PARP-1/2 inhibitors: design, synthesis and their antitumor activity.
Zhou J; Ji M; Yao H; Cao R; Zhao H; Wang X; Chen X; Xu B
Org Biomol Chem; 2018 May; 16(17):3189-3202. PubMed ID: 29648554
[TBL] [Abstract][Full Text] [Related]
16. Structure-based design of new poly (ADP-ribose) polymerase (PARP-1) inhibitors.
Chadha N; Jaggi AS; Silakari O
Mol Divers; 2017 Aug; 21(3):655-660. PubMed ID: 28653128
[TBL] [Abstract][Full Text] [Related]
17. Inducing synthetic lethality using PARP inhibitors.
Boss DS; Beijnen JH; Schellens JH
Curr Clin Pharmacol; 2010 Aug; 5(3):192-5. PubMed ID: 20406170
[TBL] [Abstract][Full Text] [Related]
18. Discovery and Characterization of (8S,9R)-5-Fluoro-8-(4-fluorophenyl)-9-(1-methyl-1H-1,2,4-triazol-5-yl)-2,7,8,9-tetrahydro-3H-pyrido[4,3,2-de]phthalazin-3-one (BMN 673, Talazoparib), a Novel, Highly Potent, and Orally Efficacious Poly(ADP-ribose) Polymerase-1/2 Inhibitor, as an Anticancer Agent.
Wang B; Chu D; Feng Y; Shen Y; Aoyagi-Scharber M; Post LE
J Med Chem; 2016 Jan; 59(1):335-57. PubMed ID: 26652717
[TBL] [Abstract][Full Text] [Related]
19. [Design, synthesis and biological evaluation of novel 3-(2-oxo-2-substituted acetamido)benzamides as PARP-1 inhibitors].
Yin YW; Ji M; Cao R; Chen XG; Xu BL
Yao Xue Xue Bao; 2015 Jun; 50(6):738-45. PubMed ID: 26521446
[TBL] [Abstract][Full Text] [Related]
20. BRCA2-deficient CAPAN-1 cells are extremely sensitive to the inhibition of Poly (ADP-Ribose) polymerase: an issue of potency.
McCabe N; Lord CJ; Tutt AN; Martin NM; Smith GC; Ashworth A
Cancer Biol Ther; 2005 Sep; 4(9):934-6. PubMed ID: 16251802
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
